Longer-Acting Drug Approved for Hepatitis C
WebMD News Archive
Jan. 31, 2001 -- "If you heard about the cure being worse than the disease, that's the way it feels," says Barb, a 50-year-old nurse in Cleveland, who is struggling with the simple act of bringing a cup of herbal tea to her lips.
Barb is in the fourth week of treatment for hepatitis C, and she has a long way to go -- 48 weeks in all to complete treatment.
Hepatitis C is often called the silent menace, a ticking time bomb that can sit within cells for decades and then suddenly flare up. Worldwide, an estimated 10 million people are infected. The virus is transmitted either by contaminated blood products -- our nation's blood supply was not protected from hepatitis C until about a decade ago -- or by IV drug abuse or needlesticks. Left untreated, it attacks the liver and can eventually cause irreversible damage, known as cirrhosis, or even cancer. At that point, the only solution is a liver transplant.
Barb's eyes are red-rimmed and watery. She is 10 pounds lighter than she was at Christmas, and even then she was carrying a spare 119 pounds on her 5-foot-8-inch frame. She says she is "tired, nauseous, and my head is pounding."
These are all fairly typical symptoms of treatment with the drug called interferon alpha-2b, long the standard treatment for hepatitis C.
Three times a week, usually about 9 p.m. when she knows she will soon be heading for bed, Barb injects herself with interferon.
"I have to keep doing this, but it's hard, because I know how I'm going to feel by morning," she says. In addition to the thrice-weekly shots, every day she takes a pill containing the antiviral drug ribavirin.
Still, Barb is hopeful. A couple of days ago, she spent the morning at the Cleveland Clinic Foundation's hepatitis C clinic. Her fellow patients and her doctor, an internist with an interest in liver diseases, were all talking about "PEG-Intron," she says. "Everyone wants to find out if they can get the new drug -- imagine, one injection a week! Like a walk in the park," she says.
Last week, the FDA approved PEG-Intron, which is basically a longer-acting version of the interferon alpha Barb currently takes.
Part of what has her hopes up -- and the hopes of her fellow patients at the hepatitis clinic -- is that they've heard that the drug's manufacturer, Schering-Plough, is claiming that a combination of ribavirin and the new long-acting PEG-Intron is more likely to knock out the hepatitis C virus than the standard interferon regimen.
Studies have shown that only about 40% of patients taking the standard treatment will have a successful response, while the response rate seen in clinical trials of PEG-Intron and ribavirin range from 42-82%.